| INTRODUC TI ON
Atherosclerotic renal artery stenosis (ARAS) accounts for an estimated 90% of renovascular disease 1 and is often complicated by renovascular hypertension, chronic kidney disease (CKD), 2 and increased adverse cardiovascular outcomes. This increased risk of cardiovascular disease and subsequent high cardiovascular mortality has resulted in significant research on how best to approach the management of these patients. 3 Research efforts have largely focused on assessing the efficacy of renal artery revascularization; however, several randomized controlled trials (RCTs) have failed to demonstrate a clear benefit of this intervention over medical therapy. 4 Current guidelines suggest that in view of these trial results, medical management with antihypertensive therapy is the preferred option for patients with renovascular disease. Drugs that interrupt the renin-angiotensin-aldosterone system (RAAS) are regarded as first-line therapy in renovascular hypertension. 5 The value of angiotensin-converting enzyme inhibitors (ACEi) may extend beyond antihypertensive properties as they protect against angiotensin II (ATII)
induced cardiovascular damage, including left ventricular hypertrophy, vascular remodeling, and activation of fibrogenic cytokines. 6 However, they reduce blood flow through the stenotic kidney, and therefore, while blood pressure may fall rapidly, there is often an ensuing deterioration in renal function 7 .Dihydropyridine calcium channel blockers (CCBs) in clinical use inhibit voltage-gated L-,T-, and P-/Q type calcium channels to different degrees of selectivity 8 and have beneficial effects on arterial smooth muscle relaxation without compromising renal function.
Furthermore, CCBs have been shown to inhibit adverse vascular remodeling. 9 However, none of these drug classes have never been specifically trialed in a renovascular hypertension cohort and experimental evidence of their effect on the progression of renal damage has been previously debated.
10
Many patients with renovascular disease have treatment-resistant hypertension, and therefore, there remain significant challenges in the control of blood pressure, resulting in the use of multiple antihypertensive agents to achieve adequate control.
11 Surprisingly, no RCTs have investigated the comparative efficacy of various antihypertensive drug classes specifically in the management of renovascular hypertension.
The aim of this study was to investigate the effect of two commonly used classes of antihypertensive agents, RAAS-blocking agents (ACEi and ARBs), and CCBs on progression of CKD and cardiovascular and allcause mortality in unilateral renal artery stenosis (URAS) and bilateral renal artery stenosis (BRAS).
| ME THODS

| Study population
This was a retrospective population-based cohort study of all hy- These ICD codes were chosen as they are used in the official national statistics for CVD. 12 Definitions of severity of stenosis based on convention used in radiological reports were as follows: mild = <50%, moderate = 50%-80%, and severe = >80%. ESRD was defined as the first reading of eGFR <15 mL/min during the follow-up period from the date of diagnosis of URAS or BRAS. eGFR was calculated from serum creatinine using the modified diet in renal disease (MDRD) equation.
Longitudinal blood pressure data were obtained using clinic BP data recorded in both primary and secondary care medical records for each patient.
| Statistical analysis
The primary outcome was defined as all-cause mortality and all major In order to determine the robustness of the findings, we also examined patient survival stratified by severity of RAS, based on the hypothesis that those with severe RAS would have a higher mortality. These time-updated Cox proportional hazard models were adjusted for age,
sex, stent placement (yes/no), presence of diabetes, use of diuretics, statins, CCB, ACEi/ARB, beta-blockers, and severity of RAS at baseline.
In order to test the assumption of proportional hazards, we generated Table 1 shows the baseline characteristics of the study population. The study consisted of 394 cases with URAS and 148 cases with BRAS.
| RE SULTS
| Baseline characteristics of the study population
Those with BRAS were significantly more likely to have stent placement and had significantly higher all-cause and CVD mortality compared to those with URAS ( Figure 1 ). Patients with URAS were also more likely to have a baseline prescription of CCB and ACEi or ARB. There were no differences in statin and aspirin exposure between groups.
| Predictors of all-cause and CVD-related mortality in URAS and BRAS using timeupdated analysis
In the study population, 50.8% (n = 86/169) of patients with BRAS and 36.8% (n = 151/410) of patients with URAS died during the follow-up period for 3.5 years. We utilized the longitudinal drug prescription data to investigate the effect of ACEi/ARB and CCB on all-cause and CVD-related mortality in both URAS and BRAS patients.
| Calcium channel blockers
In the time-updated analysis (Table 2) 
| ACE inhibitors/angiotensin receptor blockers
We found that the use of ACEi/ARBs was not associated with all-cause 
Time-updated analysis showed that increasing age, lower baseline eGFR, and increasing duration of diabetes were also independent predictors of survival in both URAS and BRAS. Interestingly, statin and aspirin exposure made no statistically significant impact on all-cause or CVD mortality in URAS or BRAS cohorts in our study.
| Blood pressure effects
To investigate whether the protective effect of CCB on RAS was mediated by a better control of blood pressure, we analyzed a subset of patients for whom longitudinal blood pressure measurements were available (n = 257 for URAS and n = 88 for BRAS). After adjustments for mean arterial pressures in this small subset of patients, CCB continued to show a statistically significant reduction in all-cause mortality in URAS population (HR = 0.42, CI = 0.23, 0.79; P = 0.006) but not in BRAS population. The results were consistent for the ACEi/ARB cohort. This subset analysis also showed that lower MAP, lower baseline eGFR, and increasing duration of diabetes were independent predictors of survival in both URAS and BRAS.
| Severity of stenosis
Finally, we wanted to investigate whether the protective effect of CCB varied according to the severity of stenosis and therefore could influence choice of therapy in patients with hypertension and different degrees of RAS. We performed a time-updated 
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| Time to ESRD in URAS and BRAS
In the study population consisting of both URAS and BRAS less than 5% patients developed ESRD. In the URAS and BRAS population combined,
there was no effect of ACEi/ARBs or CCB on delaying time to end-stage renal disease. As expected, lower baseline eGFR (P < 0.0001), higher age of diagnosis (P = 0.02), and the presence of diabetes (P = 0.02) were associated with rapid progression to ESRD. In an analysis, stratified by URAS and BRAS subgroups, no effect of ACEi/ARBs or CCB was seen.
| D ISCUSS I ON
To the best of our knowledge, this is the first cohort head-to-head study comparing effects of two commonly used medical management strategies in hypertension on CVD and overall mortality in patients with URAS and BRAS. Furthermore, we included longitudinal blood pressure control data to examine the blood pressure effect of these drugs. The main finding of our study is that CCBs were associated with a statistically significant overall survival benefit in patients with URAS and BRAS. Treatment with CCBs was also shown to be associated with reduced CVD mortality and the beneficial effects of CCBs on all-cause mortality persisted in the time-updated analysis when longitudinal blood pressure was accounted for. This beneficial effect was most pronounced in those with moderate stenosis as compared to mild or severe stenosis, suggesting that optimal timing for therapy in ARAS is also an area that requires further research.
Time-updated drug analysis did not show any effect of ACEi/ ARBs on CVD mortality in patients with established renovascular disease, with either URAS or BRAS. There was a reduction in allcause mortality in the BRAS but not URAS cohort on ACEi/ARBs.
The all-cause mortality reduction in the combined cohort is likely to be driven by the reductions seen in the BRAS cohort.
There was no effect of the different drug classes on progression of CKD to ESRD in patients with URAS or BRAS. However, numbers of patients who progressed to ESRD were small. The management of ARAS remains controversial. Revascularization was previously thought to be the mainstay of treatment, but over the last few years, large ran- is being increasingly used in these patients followed by calcium channel blockers, thiazides, and beta-blockers. Use of RAAS blockade was therefore previously thought to be contraindicated due to concerns about precipitating a decline in renal function. However, there is evidence supporting both its ability to be used in patients with renovascular disease and improved survival. 15, 16 In this present study, we did not find a significant mortality benefit with RAAS blocking agents once patients had already developed URAS or BRAS. However, we did find both overall and CVD survival benefit with CCBs. We are unable to determine with certainty whether the benefits seen with CCBs are due to blood pressure reduction alone but our longitudinal BP data suggest that this is perhaps not the case. There is certainly good experimental evidence to suggest that CCBs positively remodel vasculature in hypertension. Animal studies have suggested that dihydropyridine CCBs attenuate oxidative stress and enhance matrix metalloproteinase expression and activity.
9,17
Other concerns regarding medical management include potential progression of stenosis and occlusion and damage caused by long-term ischemia. Studies have shown that progression of URAS to ESRD is rare, 18, 19 often because cardiovascular events overtake progression to ESRD. This is in keeping with the findings of this present study. Our finding that patients with moderate stenosis benefitted most from CCB treatment would suggest that patients with established disease benefit less from CCB therapy compared to those with mild RAS, and therefore, early institution of these drugs for hypertension as per current guidelines may have added benefits.
A strength of our study is that we have examined effects of longitudinal blood pressure and anti-hypertensive treatment according to whether patients have unilateral of bilateral renal artery stenosis. We have also used longitudinal drug prescription data to look at time-updated analysis of the effect of treatment rather than examining baseline data alone. Large observational studies, conducted using large healthcare databases, can be affected by immortal time bias, which can create an impression of remarkable benefit for a drug. 20 However, the modeling of the longitudinal data using a time-updated analysis can control for this bias and helps avoid confounding by indication. In this study, we demonstrate the importance of using time-updated analysis as compared to baseline-only analysis. Our baseline analysis showed a protective effect of ACEi/ARBs on survival in RAS; however, this disappeared when we modeled the drug exposure windows using time-updated analysis.
As is common with all observational studies, our study may be subject to selection bias. However, we included all-comers within the stated timeframe. The lack of benefit observed in the BRAS group and CKD progression to ESRD may be due to small sample size and therefore lack of power. Another limitation of our study was that we used office blood pressure rather than the 24-hour ambulatory blood pressure. However, it would not have been possible to obtain longitudinal BP if restricted to 24-hour ABPM readings alone as ABPMs are not routinely used for follow-up in clinical practice. Another limitation in this study is that we are not able to adjust for longitudinal changes in dose of ACE/ARB and CCB. While we acknowledge the possibility of suboptimal dosing-which might bias these results, our data reflect real world in clinical practice in which patients with RAS and hypertension are put on the maximum tolerable dose for CCB and ACE/ ARB.
The evidence base surrounding the use of anti-hypertensive medication in patients with renovascular disease is lacking, and further evidence is required to guide medical management. Our study demonstrates the benefit of treatment of hypertension with CCBs in patients with URAS and BRAS and should provide clinicians with confidence in using this drug in patients with RAS. We would not advocate stopping the prescribing of RAAS blocking agents in patients with URAS or BRAS based on the results of this study alone. Further larger datasets should be analyzed to confirm or refute these findings. In conclusion,
we have demonstrated an overall and CVD survival benefit of treatment with CCBs in patients with both URAS and BRAS. These results require confirmation in the form of prospective randomized controlled trials.
As increasing evidence guides clinicians away from revascularization, clarification of the optimal anti-hypertensive treatment combination is required in order to guide medical management in this high-risk group of patients.
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